Related Experiment Video

Updated: Aug 17, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Marked and Durable Response to DLL3-Directed T-Cell Engager Tarlatamab in a Patient With Metastatic Pulmonary Large

Hagop Tashjian1, Sether Johnson2, Ramzi Hamouche3

  • 1Department of Medicine, University of Connecticut Health Center, Farmington, CT.

Clinical Lung Cancer
|April 15, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Cytokine release syndrome (CRS)DLL3-positive LCNECPrecision oncologyT-cell engager immunotherapyTargeted therapy

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.